You are here

Article Text

Article menu
Download PDFPDF
Letter
Late-onset MSA differs from younger-onset MSA
  1. Kurt A Jellinger
  1. Institute of Clinical Neurobiology, Vienna, Austria
  1. Correspondence to Professor Kurt A Jellinger, Institute of Clinical Neurobiology, 1150 Vienna, Austria; kurt.jellinger{at}univie.ac.at

http://dx.doi.org/10.1136/jnnp-2022-328793

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Sekiya et al1 recently reported that patients with late-onset multiple system atrophy (LO-MSA) (>75 years) show poor prognosis with median survival time of 3 years, which is significantly shorter than in those with usual-onset MSA (UO-MSA) (4.8 vs 7.9 and 3.9 vs 7.5 years, respectively). Among 276 MSA cases (193 in an autopsy cohort and 83 in a clinical cohort), LO-MSA accounted for 8% and 5%, respectively. The authors emphasised that clinical diagnosis of MSA may be difficult in elderly individuals due to the paucity of autonomic symptoms, whereas all LO-MSA patients presented with initial motor symptoms …

    View Full Text

    Footnotes

    • Contributors KAJ is the sole author.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.